Trial result ·
Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This trial tested rozanolixizumab in adults with severe fibromyalgia. Fibromyalgia brings pain all over the body, tiredness and poor sleep. The drug lowers levels of IgG antibodies in the body. In total, 63 people aged 18 to 70 took part in England. They were split by chance into groups, getting the drug or a dummy drug. Some got the drug weekly for 24 weeks, some for 12 weeks, some never.
What they found
The main test was how much pain got in the way of daily life. After 12 weeks, this score improved more with the drug than with dummy drug. But under the usual strict test, the gap could be due to chance. No serious side effects were reported by people while on the drug. Headache was the most common side effect, in drug and dummy groups. Of 63 people, 55 finished every part of the study.
What it means for patients
The authors say the drug did not work broadly in this group. The gain in this daily-life score was not meaningful for the group. The study could not pick out people with harmful antibodies. Ways to spot who may respond are needed to see if some benefit.
Why it is not certain yet
This was an early-stage trial with 63 people. The main result did not pass the usual strict test. People were not picked by whether they had harmful antibodies. This may be why results differed between people. Early trials like this cannot show for sure whether a drug works.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial.
PubMed · PMID 42748952We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Fibromyalgia publications